blog.smarttrak.comMedical Device and Wound Care News and Analysis Blog

img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443ev=PageViewnoscript=1" What We Do Real-time Market Data Consulting Services Who We Help Marketing & Product Management Business Development Clinical & Regulatory Market Research Research & Development Markets We Cover Orthopedics Wound Regenerative Medicine Neuro Therapies Resources News & Analysis Blog Industry Articles & PerspectivesMeet the Team Press Customer Testimonials News Events Careers Contact Us SmartTRAK Life Sciences News and Analysis Blog 2 min read Vaporox Company Spotlight By Susan Paquette on 5/2/24 6:33 PM New leadership at Vaporox to launch a second generation of vaporous hyperoxia therapy at SAWC Spring 2024. With the upcoming launch of its second-generation Vaporous Hyperoxia Therapy (VHT-200), Denver, CO-based Vaporox is well positioned to treat a wide range of chronic, hard-to-heal wounds and expand the company’s presence in the almost five billion dollar US Market for Advanced Wound Care. SmartTRAK spotlights the company, its latest research and VHT, a breakthrough technology designed to accelerate wound healing when combined with standard or advanced wound care. In this comprehensive SmartTRAK Perspective article, available for download , we delve deep into Vaporox, exploring a variety of detailed topics, including: The Overview Vaporox CEO and President Alan Sage, a successful start-up entrepreneur, brings his decades of experience to the medical device industry to bring VHT-200 to market. The novel technology was developed as a result of work at UCLA Medical Center for children with debilitating bed sores ... Technology/Key Differentiator VHT delivers a unique combination of elements that accelerate healing: ultrasonic mist and concentrated oxygen. Vaporox administers these elements in a patented, automated, dual-modality system ... Market Potential After starting in the diabetic foot ulcer (DFU) space, the company has quickly expanded into facilities treating all types of wounds, including venous leg ulcers (VLUs), dehisced post-surgical wounds, burns and pressure injuries ... Business Model/Financing The Vaporox business model provides the device to the clinician at no cost and charges for the disposable and pay-per-use fees ... Clinical/Regulatory Status Vaporox received FDA 510(k) clearance for the second-generation VHT-200 product in the spring of 2023 ... Reimbursement VHT is a low-frequency, non-contact, non-thermal ultrasonic mist therapy. It is an FDA-cleared technology that has been clinically validated as a safe and effective adjunctive treatment for healing nine types of skin wounds ... Goals The company just hired a new vice president of sales and marketing and is aggressively pursuing high-volume private-practice podiatric surgeons, medical doctors, and nursing facilities ... To download and read the complete "Vaporox Company Spotlight" perspective article by Susan Paquette, SmartTRAK VP & General Manager, Wound, just click the button below. Topics: Wound Care Continue Reading 3 min read Inceptiv SCS: Offering Options in a Closed-Loop Device By Anne Staylor on 4/26/24 11:56 AM Medtronic’s David Carr, VP & GM, Pain Interventions, discusses Inceptiv closed-loop SCS in an interview with SmartTRAK. Medtronic (MDT) announced FDA approval for the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS), the second closed-loop SCS device to reach the market using evoked compound action potentials (ECAPS). The company previously launched Inceptiv in Europe and Japan and plans to initiate Inceptiv’s US market launch in the coming weeks. SmartTRAK recently interviewed David Carr , MDT’s vice president and general manager of Pain Interventions, to learn more about Inceptiv, what differentiates it from other SCS devices and what it means for Medtronic and the SCS market. To listen to the interview, click on the following video (22:54 min). A link to download the complete transcript of the interview is also provided below. Anne Staylor here with BiomedGPS. Today, I am talking with David Carr, who is the vice president and general manager of Pain Interventions at Medtronic. Exciting news, David. Medtronic now has FDA approval for your Inceptiv SCS device, an ECAPs-based device. So David, tell me what does Inceptiv mean for Medtronic? David Carr: Good afternoon, Anne, and thank you for your time today and your interest in this announcement for us. This is a big moment for Medtronic and especially for the pain team within Medtronic. This is technology that has taken many, many years to develop. If you think back to the pivotal RCT, we did ECHOMAC, which demonstrated the performance of closed-loop technology, the algorithm, many years ago. Six published manuscripts across many recognized journals. Twenty peer-reviewed abstracts and posters, data from over 200 patients and several million ECAPs. So this is not something that’s just been developed in the last couple of years. There’s been a tremendous amount of work invested in this platform. So this is a very big moment for Medtronic, finally getting approval with the FDA to launch the product in the US market. Because as you know, we’ve already launched this product in Europe and Japan, and we’re already seeing the tremendous patient benefits that the product brings to the market. Let’s start by having you talk about the technology itself. What are the key differentiators for Inceptiv versus other ECAPs-based devices on the market? DC: Well, there’s only one other ECAP-based product on the market, and that product is essentially closed-loop paresthesia. Okay, what differentiates this product is ... To download and read the complete interview "Inceptiv SCS: Offering Options in a Closed-Loop Device" with David Carr, VP and GM of Pain Interventions at Medtronic, just click the button below. Topics: Neuro Therapies Continue Reading 3 min read Three Global Spine Robotics Start-ups to Watch in 2024 By Shelly Caruso on 4/23/24 9:45 AM SmartTRAK highlights three innovative start-ups with next-gen spine robots in development: Cyber Surgery, LEM Surgical and SpinEM Robotics. The landscape of spine robotics has undergone a remarkable transformation in recent years, with advancements in technology revolutionizing the approach to spinal surgeries. As we step into 2024, there’s a race in the Spine Enabling Technology Market among companies to develop state-of-the-art robotic systems. The demand for minimally invasive spinal surgeries has been a driving force in the evolution of spine-enabling technologies. In this article , available for download , SmartTRAK explores in detail three innovative start-ups with next-gen spine solutions in development. They are: Cyber Surgery: A Modular System to Improve Minimally Invasive Spine Surgery Cyber Surgery, a Spain-based healthcare technology startup specializing in medical robotics, is developing ALAYA, a robotic navigation system that uses internally developed haptic technology, which Cyber Surgery says is more precise and user-friendly than optical navigation systems. The company touts the system as ... ( read more ) LEM Surgical: A Unique Multi-armed Approach to Spine Robotics Founded in 2021 and based in Bern, Switzerland, LEM Surgical takes a unique approach to spine robotics. Although LEM Surgical has held its robotic project, Sapien, in stealth mode, the company is looking toward ... ( read more ) SpinEM Robotics: A Tracking Solution for Precision in Robotic Spine Surgery SpinEM was founded in 2021 and is headquartered in France. The company is supported by local industrial partners and a start-up factory in Grenoble. In January 2024, Haventure, an international accelerator for digital surgery and robotics start-ups, announced that ... ( read more ) As Cyber Surgery, LEM Surgical and SpinEM Robotics pave the way for next-gen spine robotics, the market is poised for a significant transformation. These companies bring a unique set of...